Biosense Webster

Company Overview

Snapshot

Founded in September 1993, Biosense Webster operates with over 3,000 employees. The company was acquired by Johnson & Johnson in September 1997 for $400 million in shares, becoming part of Cordis, a Johnson & Johnson subsidiary.

Business overview

Biosense Webster develops advanced solutions for the diagnosis and treatment of cardiac arrhythmias, aiming to enhance procedural methodologies and improve success rates for physicians. Its core technology includes CARTO Solutions, which provide navigational and mapping features, integrating multiple datasets and images into a single resource for detailed, real-time information. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices, Diagnostics Devices, and Medical Treatment & Therapeutics, serving healthcare providers globally.

Strategic signal

In October 2022, Biosense Webster launched the HELIOSTAR Balloon Ablation Catheter in Europe, marking a significant advancement as the first radiofrequency balloon ablation catheter. This innovation, fully integrated with the CARTO 3 System, allows for single-shot pulmonary vein isolation in 12 seconds, offering shorter procedure times and reduced radiation exposure. This launch signals the company's continued leadership in cardiac electrophysiology and its commitment to developing efficient, high-impact technologies for atrial fibrillation treatment.

Company Intelligence Q&A

What was a significant product launch by Biosense Webster in Europe?

In October 2022, Biosense Webster launched the HELIOSTAR Balloon Ablation Catheter in Europe. This is the first radiofrequency balloon ablation catheter, designed to enable physicians to perform more efficient cardiac ablations by achieving single-shot pulmonary vein isolation in 12 seconds.

What new mapping catheter did Biosense Webster launch in September 2022?

In September 2022, Biosense Webster launched the OCTARAY Mapping Catheter with TRUEref Technology, further expanding its portfolio of advanced diagnostic tools for cardiac arrhythmias.

When was Biosense Webster acquired and by whom?

Biosense Webster was acquired by Johnson & Johnson in September 1997. The acquisition was valued at $400 million in Johnson & Johnson shares, and Biosense became part of Cordis, a Johnson & Johnson subsidiary.

What was a key development regarding catheter reprocessing involving Biosense Webster's products?

In July 2019, Innovative Health received FDA clearance to reprocess the Biosense Webster PentaRay Nav eco high-density mapping catheter for reuse. This development allows hospitals to potentially save significant costs on atrial fibrillation procedures.

What cloud-based network did Biosense Webster launch in May 2019?

In May 2019, Biosense Webster launched a cloud-based cardiac ablation data network. This initiative aims to enhance data management and analysis for cardiac ablation procedures.